CB Insights released a list of what it deems to be the 50 most promising digital health companies of 2023. The market research firm said that the startups on the list are working to improve four main aspects of healthcare: personalization, efficiency, equity and accessibility.
The healthcare AI space will be an exciting one to watch over the next couple years, as investment dollars flow to startups and providers launch more AI pilots. Two of the most interesting trends to watch will be the use cases that healthcare organizations prioritize when deploying generative AI models, as well as M&A activity within the healthcare AI field, a CB Insights analyst declared during a recent webinar.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
There are three key areas of the healthcare sector where generative AI is booming the most — in terms of both venture capital funding and the development of innovative technology — according to Anjalika Komatireddy, an analyst at CB Insights. During a recent webinar, she discussed the generative AI activity occurring in these three areas: care delivery and navigation, digital therapeutics and drug discovery.
Digital health's investment slowdown is so severe that the fourth quarter of 2022 marked the lowest quarterly digital health funding total in the past five years, according to new report. Q4 was also the first quarter with no new unicorn births since 2018.
A new CB Insights report found global digital health funding fell 36 percent in the first quarter of the year from that in Q4, 2021, with mental health and digital therapeutics suffering the greatest quarter-on-quarter decline.
In the second quarter of 2021, the top five deals alone were worth $1.6 billion, representing 30% of the total funding raised. In addition, six telehealth companies joined the unicorn club, including LetsGetChecked and Thirty Madison.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
A few areas recently targeted by investors have been companies utilizing AI in healthcare, as well as mental health and wellness startups.
The most recent MoneyTree report from PwC and CB Insights highlights the biggest biotech-related and medical devices VC deals in Q2, which include investments in companies like Grail, Allogene Therapeutics, RefleXion Medical and Mevion Medical Systems.
The largest acquirers tended to be health IT vendors but what's interesting about the report by CB Inisghts is that it shows the diversity of companies they've pursued.
Zenefits survived as a unicorn despite a major devaluation in 2016. Theranos did not. Human Longevity and Flatiron Health joined the exclusive club.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
CB Insights reports a slight slowdown in digital health M&A deals for the first six months of 2016, which added up to 78 for the first half of 2016 compared with 165 for the full year in 2015.
CB Insights digital health stats for Q4 added up for the full year 2015 reveal $4.6 billion in digital health deals. It is part of a larger look at technology investments in 2015?.
CB Insights highlights some of the interesting healthcare applications for the Internet of Things from swallowable sensors to smart glasses.
M&A dealflow among VC-backed digital health companies has been strong but the pace of IPOs has slackened.
CB Insights blog entry looking at the past five years of digital health gives a big picture glimpse of the pace, size and stage of investments.